LOGIN
ID
PW
MemberShip
2025-02-07 04:13
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
China rises as global R&D leader, K-bio not in top 50
by
Cha, Jihyun
Feb 6, 2025 05:57am
The R&D investment gap between Korean biopharmaceutical companies and Big Pharma is increasing. Analysis suggests that Korean companies must seek measures to respond to competition for next-generation technology as the R&D investment centers around the United States and China. On February 5, the Korea Chamber of Commerce and Industry (KCCI) a
Company
Baxter¡¯s Renal Care Unit spinoff Vantive is launched
by
Whang, byung-woo
Feb 6, 2025 05:56am
With the acquisition process complete for Baxter's Renal Care business, it has newly launched as Vantive, a new company specializing in kidney and life-sustaining organ therapies. The spin-off follows the acquisition of Baxter's Kidney Care business by funds managed by global investment firm The Carlyle Group. As an independent company
Company
Imminent launch of the 3rd new CAR-T-cell therapy 'Yescarta'
by
Eo, Yun-Ho
Feb 6, 2025 05:56am
The third CAR-T-cell therapy 'Yescarta' is expected to be commercialized in South Korea. According to industry sources, Gilead Sciences submitted documentation for the approval of the CAR-T-cell therapy, Yescarta (axicabtagene ciloleucel), and the Ministry of Food and Drug Safety (MFDS) is currently conducting the review. Yescarta was
Company
1st to exceed KRW 1T sales¡¦Pfizer's ESG initiatives
by
Whang, byung-woo
Feb 5, 2025 05:52am
Pfizer Korea, the first to exceed KRW 1 trillion in sales from COVID-19 vaccine¡¤treatments, continues strengthening its sustainable business management based on the ESG initiative. After recording KRW 3 trillion in 2022 during the COVID-19 pandemic, Pifzer Korea's sales robustly decreased. However, despite unusual circumstances, the i
Company
Multiple sclerosis drug Ocrevus may soon be reimbursed
by
Eo, Yun-Ho
Feb 5, 2025 05:52am
The new multiple sclerosis drug Ocrevus is expected to be listed for reimbursement in Kore. According to industry sources, Roche Korea has completed negotiations with the National Health Insurance Service on the drug price of Ocrevus (ocrelizumab) for relapsing multiple sclerosis (MS). As a result, the drug is expected to be reimbursed
Company
Hepatitis B drug market remakes ₩300B after 6 years
by
Kim, Jin-Gu
Feb 4, 2025 05:55am
The outpatient prescription market for hepatitis B drugs expanded again last year to exceed KRW 300 billion. This is the first time the market has exceeded the mark in 6 years since 2018. Gilead Sciences¡¯ Vemlidy drove the market growth with a 15% increase in sales from KRW 61.9 billion to KRW 71.3 billion in 1 year, while the combined pres
Company
'Tibsovo' reapplies for bile duct cancer indication reimb
by
Eo, Yun-Ho
Feb 4, 2025 05:55am
'Tibsovo,' which is indicated for the treatment of bile duct cancer (cholangiocarcinoma) and acute myeloid leukemia (AML), reapplies for obtaining insurance reimbursement. According to industry sources, Servier Korea has submitted a reimbursement application for cholangiocarcinoma indication of Tibsovo (ivosidenib), a drug targeting the i
Company
Lixiana leads the DOAC market..generics make advances
by
Kim, Jin-Gu
Feb 4, 2025 05:55am
Daiichi Sankyo's Lixiana (edoxaban) is further solidifying its dominance in the direct-acting oral anticoagulant (DOAC) market. Prescriptions grew 12% year-on-year, and its share of the total market expanded to 45%. Sales of Eliquis (apixaban) and Xarelto (rivaroxaban), on the other hand, have faltered. Eliquis saw its first year-over-
Company
ROS1 targeted cancer drug 'Augtyro' nearing mkt entry
by
Eo, Yun-Ho
Feb 3, 2025 05:52am
The ROS1-targeting anticancer drug, 'Augtyro,' is expected to be commercialized in South Korea. According to industry sources, Bristol Myers Squibb (BMS) Korea is close to receiving approval from the Ministry of Food and Drug Safety (MFDS) for Augtyro (repotrectinib), an anticancer drug that can be used regardless of cancer types. This
Company
Samsung Bioepis loses Eylea appeal trial in the US
by
Cha, Jihyun
Feb 3, 2025 05:52am
The U.S. market entry of 'Eylea' biosimilar, a treatment for eye diseases, from Samsung Bioepis is stalled. The company recently lost a trial of appeal in addition to the previous motion filed by the developer for a preliminary injunction over a sales ban on an item. According to the biotechnology industry sources on January 31, the United S
1
2
3
4
5
6
7
8
9
10
>